UBS Group’s Phathom Pharmaceuticals PHAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.02M | Sell |
419,473
-288,105
| -41% | -$2.76M | ﹤0.01% | 3240 |
|
|
2025
Q1 | $4.44M | Buy |
707,578
+241,962
| +52% | +$1.52M | ﹤0.01% | 3060 |
|
|
2024
Q4 | $3.78M | Buy |
465,616
+393,675
| +547% | +$3.2M | ﹤0.01% | 3224 |
|
|
2024
Q3 | $1.3M | Buy |
71,941
+28,855
| +67% | +$522K | ﹤0.01% | 3374 |
|
|
2024
Q2 | $444K | Sell |
43,086
-6,837
| -14% | -$70.4K | ﹤0.01% | 4004 |
|
|
2024
Q1 | $530K | Buy |
49,923
+10,491
| +27% | +$111K | ﹤0.01% | 4064 |
|
|
2023
Q4 | $360K | Buy |
39,432
+5,732
| +17% | +$52.3K | ﹤0.01% | 4210 |
|
|
2023
Q3 | $349K | Buy |
33,700
+16,894
| +101% | +$175K | ﹤0.01% | 3858 |
|
|
2023
Q2 | $241K | Buy |
+16,806
| New | +$241K | ﹤0.01% | 4336 |
|
|
2023
Q1 | – | Sell |
-795
| Closed | -$8.92K | – | 8886 |
|
|
2022
Q4 | $8.92K | Buy |
795
+167
| +27% | +$1.87K | ﹤0.01% | 7516 |
|
|
2022
Q3 | $7K | Buy |
+628
| New | +$7K | ﹤0.01% | 7789 |
|
|
2022
Q1 | – | Sell |
-1,329
| Closed | -$26K | – | 9493 |
|
|
2021
Q4 | $26K | Buy |
+1,329
| New | +$26K | ﹤0.01% | 6429 |
|
|
2021
Q3 | – | Sell |
-699
| Closed | -$24K | – | 8670 |
|
|
2021
Q2 | $24K | Sell |
699
-2,178
| -76% | -$74.8K | ﹤0.01% | 6054 |
|
|
2021
Q1 | $108K | Buy |
2,877
+220
| +8% | +$8.26K | ﹤0.01% | 4919 |
|
|
2020
Q4 | $88K | Buy |
2,657
+1,283
| +93% | +$42.5K | ﹤0.01% | 4784 |
|
|
2020
Q3 | $50K | Sell |
1,374
-2,803
| -67% | -$102K | ﹤0.01% | 4801 |
|
|
2020
Q2 | $137K | Sell |
4,177
-2,238
| -35% | -$73.4K | ﹤0.01% | 4266 |
|
|
2020
Q1 | $166K | Sell |
6,415
-7,684
| -55% | -$199K | ﹤0.01% | 4031 |
|
|
2019
Q4 | $439K | Buy |
+14,099
| New | +$439K | ﹤0.01% | 3996 |
|